Frehemgo Denecimig EU Approval: Novo’s Monthly Haemophilia A Shot Takes On Hemlibra
The EU has approved Novo Nordisk Frehemgo (denecimig), a monthly, fortnightly or weekly pen for haemophilia A with or without inhibitors.
The EU has approved Novo Nordisk Frehemgo (denecimig), a monthly, fortnightly or weekly pen for haemophilia A with or without inhibitors.
FDA extended its denecimig review as manufacturing-site remediation continues. No efficacy or safety issues were cited; Novo now expects a US launch in H1 2027.